Акушерство и Гинекология Санкт-Петербурга. 2017; : 43-46
Выбор метода лечения миомы матки при бесплодии
Аннотация
Частота миомы матки в популяции составляет 20 – 25%, а после 35 лет она достигает 52%. Однако только 20% всех миоматозных узлов является «симптомными». В статье представлен современный взгляд на консервативные и органосохраняющие хирургические методы лечения миомы матки. Проанализированы результаты и репродуктивные исходы миомэктомий, проведенных на базе эндоскопического отделения ГБУЗ МО МОНИИАГ с 2010 по 2014 гг.
Вывод: мы считаем, что миомэктомия при симптомной миоме матки является безопасным вмешательством, позволяющим сохранить репродуктивную функцию при незначительном количестве осложнений.
Список литературы
1. Сидорова И.С. Миома матки. Москва: МИА. 2003.
2. Klatsky P.C., Tran N.D., Caughey A.B., Fujimoto V.Y. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol. 2008; 198 (4):357-366. Doi: 10.1016/j.ajog.2007.12.039.
3. Carranza-Mamane B., Havelock J., Hemmings R., Cheung A., Sierra S., Case A., Dwyer C., Graham J., Liu K., Murdock W., Vause T., Wong B., Burnett M. The management of uterine fibroids in women with otherwise unexplained infertility. J Obstet Gynaecol Can. 2015; 37 (3):277-288. doi: 10.1016/S1701-2163(15)30318-2. French.
4. Zepiridis L.I., Grimbizis G.F., Tarlatzis B.C. Infertility and uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2016; 34:66-73. doi: 10.1016/j.bpobgyn.2015.12.001
5. Moroni R., Vieira C., Ferriani R., Candido-Dos-Reis F., Brito L. Pharmacological treatment of uterine fibroids. Ann Med Health Sci Res. 2014; 4 (Suppl 3):S185192. doi: 10.4103/2141-9248.141955.
6. Senol T., Kahramanoglu I., Dogan Y., Baktiroglu M., Karateke A., Suer N. Levonorgestrel-releasing intrauterine device use as an alternative to surgical therapy for uterine leiomyoma. Clin Exp Obstet Gynecol. 2015; 42 (2):224-227.
7. Machado R.B., de Souza I.M., Beltrame A., Bernardes C.R., Morimoto M.S., Santana N. The levonorgestrel-releasing intrauterine system: its effect on the number of hysterectomies performed in perimenopausal women with uterine fibroids. Gynecol Endocrinol. 2013; 29 (5):492-495. Doi: 10.3109/09513590.2013.769517.
8. Willame A., Marci R., Petignat P., Dubuisson J. Myoma migration: an unexpected “effect” with Ulipristal acetate treatment. Eur Rev Med Pharmacol Sci. 2016; 20 (8):1439-1444.
9. Puchar A., Luton D., Koskas M. Ulipristal acetate for uterine fibroid-related symptoms. Drugs Today (Barc). 2015; 51 (11):661-667. Doi: 10.1358/dot.2015.51.11.2413469.
10. Luyckx M., Squifflet J.L., Jadoul P., Votino R., Dolmans M.M., Donnez J. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril. 2014; 102 (5):1404-1409. Doi: 10.1016/j.fertnstert.2014.07.1253.
11. Olejek A., Olszak-Wąsik K., Czerwinska-Bednarska A. Long-term intermittent pharmacological therapy of uterine fibroids a possibility to avoid hysterectomy and its negative consequences. Prz Menopauzalny. 2016; 15 (1):48-51. doi: 10.5114/pm.2016.58774.
12. Sizzi O., Rossetti A., Malzoni M., Minelli L., La Grotta F., Soranna L., Panunzi S., Spagnolo R., Imperato F., Landi S., Fiaccamento A., Stola E. Italian multicenter study on complications of laparoscopic myomectomy. JSLS. 2007; 14 (4):45362. DOI: 10.1016/j.jmig.2007.01.013.
Obstetrics and Gynaecology of Saint-Petersburg. 2017; : 43-46
The choice of treatment of fibroids in related infertility
Abstract
Incidence of uterine fibriods in women population is 20% 25%. At the age of 35 years the incidence increased to 52%, but only 20% of all fibroids became symptomatic. This article presents a modern view of conservative and surgical treatment of uterine fibroids. We analyzed the results and reproductive outcomes of myomectomy, which are performed at our department from 2010 to 2014. Conclusion: myomectomy in symptomatic myoma is a safety procedure with low rate of complications.
References
1. Sidorova I.S. Mioma matki. Moskva: MIA. 2003.
2. Klatsky P.C., Tran N.D., Caughey A.B., Fujimoto V.Y. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol. 2008; 198 (4):357-366. Doi: 10.1016/j.ajog.2007.12.039.
3. Carranza-Mamane B., Havelock J., Hemmings R., Cheung A., Sierra S., Case A., Dwyer C., Graham J., Liu K., Murdock W., Vause T., Wong B., Burnett M. The management of uterine fibroids in women with otherwise unexplained infertility. J Obstet Gynaecol Can. 2015; 37 (3):277-288. doi: 10.1016/S1701-2163(15)30318-2. French.
4. Zepiridis L.I., Grimbizis G.F., Tarlatzis B.C. Infertility and uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2016; 34:66-73. doi: 10.1016/j.bpobgyn.2015.12.001
5. Moroni R., Vieira C., Ferriani R., Candido-Dos-Reis F., Brito L. Pharmacological treatment of uterine fibroids. Ann Med Health Sci Res. 2014; 4 (Suppl 3):S185192. doi: 10.4103/2141-9248.141955.
6. Senol T., Kahramanoglu I., Dogan Y., Baktiroglu M., Karateke A., Suer N. Levonorgestrel-releasing intrauterine device use as an alternative to surgical therapy for uterine leiomyoma. Clin Exp Obstet Gynecol. 2015; 42 (2):224-227.
7. Machado R.B., de Souza I.M., Beltrame A., Bernardes C.R., Morimoto M.S., Santana N. The levonorgestrel-releasing intrauterine system: its effect on the number of hysterectomies performed in perimenopausal women with uterine fibroids. Gynecol Endocrinol. 2013; 29 (5):492-495. Doi: 10.3109/09513590.2013.769517.
8. Willame A., Marci R., Petignat P., Dubuisson J. Myoma migration: an unexpected “effect” with Ulipristal acetate treatment. Eur Rev Med Pharmacol Sci. 2016; 20 (8):1439-1444.
9. Puchar A., Luton D., Koskas M. Ulipristal acetate for uterine fibroid-related symptoms. Drugs Today (Barc). 2015; 51 (11):661-667. Doi: 10.1358/dot.2015.51.11.2413469.
10. Luyckx M., Squifflet J.L., Jadoul P., Votino R., Dolmans M.M., Donnez J. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril. 2014; 102 (5):1404-1409. Doi: 10.1016/j.fertnstert.2014.07.1253.
11. Olejek A., Olszak-Wąsik K., Czerwinska-Bednarska A. Long-term intermittent pharmacological therapy of uterine fibroids a possibility to avoid hysterectomy and its negative consequences. Prz Menopauzalny. 2016; 15 (1):48-51. doi: 10.5114/pm.2016.58774.
12. Sizzi O., Rossetti A., Malzoni M., Minelli L., La Grotta F., Soranna L., Panunzi S., Spagnolo R., Imperato F., Landi S., Fiaccamento A., Stola E. Italian multicenter study on complications of laparoscopic myomectomy. JSLS. 2007; 14 (4):45362. DOI: 10.1016/j.jmig.2007.01.013.
